Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment
Combined therapy has become a pivotal direction in NSCLC systemic treatment and future research should prioritize optimizing treatment regimens, refining real-world safety assessments, and expanding clinical application in patients with complex comorbidities to address current unmet therapeutic needs.